Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment

Blood Cancer J. 2014 Aug 1;4(8):e235. doi: 10.1038/bcj.2014.56.

Abstract

Reversal of renal dysfunction significantly affects the prognosis of multiple myeloma (MM) with renal impairment (RI). There is no reliable test for predicting reversibility of RI in MM patients. We postulated that MM with high albuminuria may reflect glomerular disease that is difficult to reverse. Here, we examined the impact of urinary albumin excretion. We retrospectively analyzed 279 patients admitted to our hospital from April 2000 to December 2013. Clinical variables and laboratory data that may affect myeloma treatment response were extracted. The results were examined for relationship to renal response by univariate and multivariate analysis. RI (estimated glomerular filtration rate ≦50 ml/min per 1.73 m(2)) was observed in 116 patients (46%) and renal responses of renal complete response, renal partial response, renal minor response and no response were obtained in 46 (40%), 15 (13%), 13 (11%) and 42 (36%) patients, respectively. Although renal recovery was significantly associated with Durie-Salmon 1 or 2 (P=0.02), myeloma response better than very good partial response (P=0.03), involved free light-chain (iFLC) reduction from baseline 80% at day 12 (P=0.005), ≧95% at day 21 (P<0.001) and urinary albumin ≦25% on admission (P<0.001) on univariate analysis, only reduction of iFLC 95% at day 21 (P=0.015) and urinary albumin ≦25% (P=0.007) remained significant for any renal response. Our observation indicates that increased urinary albumin excretion >25% and reduction of iFLC ≦95% on day 21 were associated with favorable renal recovery in MM patients with RI, and were considered as negative predictors for renal response.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Albuminuria* / blood
  • Albuminuria* / mortality
  • Albuminuria* / urine
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate
  • Humans
  • Immunoglobulin Light Chains / blood*
  • Kidney Diseases* / blood
  • Kidney Diseases* / mortality
  • Kidney Diseases* / urine
  • Male
  • Middle Aged
  • Multiple Myeloma* / blood
  • Multiple Myeloma* / mortality
  • Multiple Myeloma* / urine
  • Retrospective Studies
  • Survival Rate

Substances

  • Immunoglobulin Light Chains